A class of anticancer treatment, also known as ADCs, that are partially comprised of a monoclonal antibody. ADCs combine the selectiveness of targeted treatment with the potency of chemotherapy drugs.
LATEST ARTICLES
Building "Smart Bombs" to Attack Cancer
Biopharmaceutical researchers are investigating a new type of therapy that has the potential to attack cancer cells while leaving healthier cells unharmed.
RELATED ARTICLES
Researcher Profile: Nils Lonberg
In his role as senior vice president of oncology biology discovery at Bristol-Myers Squibb, Dr. Lonberg leads a drug discovery group responsible for identifying potential immuno-oncology (I-O) treatments.
